How Taking into Account the Pyloric Tonus Contributes to Treatment Success While Administering Gastric "Botulinum Toxin A" for Weight Loss
- PMID: 32405906
- DOI: 10.1007/s11695-020-04556-7
How Taking into Account the Pyloric Tonus Contributes to Treatment Success While Administering Gastric "Botulinum Toxin A" for Weight Loss
Abstract
Purpose: To analyze how considering the structure of normotonic pylorus (NP) or hypotonic pylorus (HP) contributes to treatment success in patients administered gastric botulinum toxin A for weight loss.
Materials and methods: We measured body mass indexes (BMIs) of the patients who applied for gastric botulinum toxin A (BTA) for weight loss, before and 6 months after the procedure. The patients' pylori were classified as normotonic pylorus (NP) if, during endoscopy, they had a normal peristaltic motion and was closing completely, and as hypotonic pylorus if they were not closing properly or were aperistaltic. We compared the patients' mean pre-operative and 6-month post-operative BMIs. The groups were compared using the chi-square test where a p ˂ 0.05 was considered significant.
Results: The study included 178 patients administered gastric BTA. In the assessment made without considering the pyloric structure, the mean BMI decreased from 34.76 ± 7.65 to 33.09 ± 7.80 kg/m2, while the difference was not statistically significant (p ˂ 0.06). Conversely, in the analysis performed considering the structure of pylorus, the mean pre-operative BMI of the 45 patients with HP structure was 35.16 ± 7.07 kg/m2 which decreased to 35.11 ± 7.03 kg/m2 6 months after the procedure; hence, the difference was not statistically significant (p ˂ 0.7). The mean pre-operative BMI of the 133 patients with NP structure, 34.63 ± 7.84 kg/m2, decreased to 32.40 ± 8.05 kg/m2 6 months after the procedure and the difference was statistically significant (p ˂ 0.05)*.
Conclusion: We advise to be selective in BTA administration and to administer BTA to the patients who, endoscopically, have a NP structure.
Keywords: Gastric Botox; Hypotonic pylorus; Normotonic pylorus; Obesity.
References
-
- Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17. https://doi.org/10.1007/978-3-319-48382-5_1 . - DOI - PubMed
-
- Sanchez Torralvo FJ, Valdés Hernandez S, Tapia MJ, et al. Intragastric injection of botulinum toxin. A real alternative for obesity treatment? A systematic review. Nutr Hosp. 2017;34(5):1482–8. https://doi.org/10.20960/nh.1220 . - DOI - PubMed
-
- Freire R. Scientific evidence of diets for weight loss: different macronutrient composition, intermittent fasting, and popular diets. Nutrition. 2019;69:110549. https://doi.org/10.1016/j.nut.2019.07.001 . - DOI - PubMed
-
- Cano-Ibáñez N, Bueno-Cavanillas A, Martínez-González MÁ, et al. Effect of changes in adherence to Mediterranean diet on nutrient density after 1-year of follow-up: results from the PREDIMED-plus study. Eur J Nutr. 2019; https://doi.org/10.1007/s00394-019-02087-1 .
-
- Coşkun H, Duran Y, Dilege E, et al. Intragastric injection of botulinum toxin. Is it a real alternative to the treatment of obesity? Obes Surg. 2005;15(8):1137–43. https://doi.org/10.1381/0960892055002275 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
